The OVATURE (OVArian TUmor REsponse) study sponsor, Marshall Edwards, Inc. seeks investigators for this Phase III study, which will be investigating the efficacy and safety of phenoxodiol in combination with a weekly carboplatin regimen in patients with progressive or recurrent ovarian cancer that has become resistant or refractory to second line platinum therapy. This is an exciting trial as it provides the opportunity to investigate the efficacy and safety of phenoxodiol as a chemosensitizing agent in this indication as well as to explore further the use of a weekly dose of carboplatin for this patient population.

This study protocol has been evaluated by the FDA under the Special Protocol Assessment (SPA) process. Dr. Thomas Rutherford of Yale University Hospital is the coordinating Principal Investigator (PI) in the U.S. for this study.

To obtain more information, contact Patti Rossi, Pharm.D., Vice President-Clinical Operations, Marshall Edwards, Inc. at patti.rossi@marshalledwardsinc.com.

To learn more about how phenoxodiol works, you can view the animation below.